Erratum.

Abstract

Journal of DiabetesVolume 10, Issue 5 p. 423-423 ErratumFree Access Erratum This article corrects the following: Comparison of insulin lispro mix 25 with insulin lispro mix 50 as insulin starter in Chinese patients with type 2 diabetes mellitus (CLASSIFY study): Subgroup analysis of a Phase 4 open-label randomized trial Qing Su, Chao Liu, Hongting Zheng, Jun Zhu, Peng Fei Li, Lei Qian, Wen Ying Yang, Volume 9Issue 6Journal of Diabetes pages: 575-585 First Published online: September 26, 2016 First published: 06 April 2018 https://doi.org/10.1111/1753-0407.12656AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat In 1, the data under the fifth column ‘LS mean change from baseline (95% CI)’, 1st and 2nd entries of row ‘HbA1c (%)’ of Table 3 were published incorrectly. The corrected Table 3 is shown below. Table 3. Change from baseline at Week 26 for primary (HbA1c) and secondary (fasting blood glucose, 1,5-anhydroglucitol) efficacy measures Treatment (n) Baseline Endpoint LS mean change from baseline (95% CI) Difference (95% CI) in LS mean change from baseline P-value HbA1c (%) LM25 (72) 8.6±1.1 7.1±0.8 -1.55 (-1.73, -1.36) 0.48 (0.22, 0.74) <0.001 LM50 (69) 8.5±1.1 6.5±0.6 -2.03 (-2.21, -1.84) FBG (mmol/L) LM25 (80) 9.6±2.3 7.2±1.6 -2.50 (-2.89, -2.11) -0.38 (-0.94, -0.18) 0.180 LM50 (76) 9.7±2.3 7.6±1.8 -2.12 (-2.53, -1.72) 1,5-AG (μg/mL) LM25 (80) 5.16±4.43 10.24±8.30 5.03 (3.49, 6.57) -2.72 (-4.92, -0.52) 0.016 LM50 (76) 5.75±5.60 12.99±6.56 7.75 (6.16, 9.34) Unless indicated otherwise, data are given as the mean ± SD. 1,5-AG, 1,5-anhydroglucitol; CI, confidence interval; FBG, fasting blood glucose; LM25, insulin lispro mix 25; LM50, insulin lispro mix 50; LS, least squares; T2DM, type 2 diabetes mellitus. The corresponding in-text citation on page 578-579 has been corrected and the statement should read as follows: “The decrease from baseline in mean HbA1c levels was significantly higher in the LM50 treatment group (LS mean change –2.03 %; 95 % CI -2.21, -1.84; P< 0.001) than in the LM25 treatment group (LS mean change -1.55%; 95 % CI -1.73, -1.36) at Week 26 (Table 3).” The authors apologize for this error and regret any inconvenience it may have caused. Reference 1Su Q, Liu C, Zheng H et al. Comparison of insulin lispro mix 25 with insulin lispro mix 50 as insulin starter in Chinese patients with type 2 diabetes mellitus (CLASSIFY study): Subgroup analysis of a Phase 4 open-label randomized trial. Journal of Diabetes. 2016; 9: 575– 585. Volume10, Issue5May 2018Pages 423-423 ReferencesRelatedInformation